EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Victor Wasehuus iD, J David Smeijer iD, Phil Ambery iD, Peter J Greasley, Emma Wijkmark, David C Wheeler, Peter Rossing iD, Hiddo J L Heerspink iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16468 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Victor Wasehuus und 7 weiteren Autor:innen. Beteiligte Einrichtung: Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD). Methods and Materials We conducted a post hoc analysis of the ZENITH‐CKD trial, a multicentre 12‐week, double‐blind, randomized, active‐controlled, phase 2b study involving 447 participants with CKD (261 with and 186 without type 2 diabetes). Participants were assigned to zibotentan (0.25 or 1.5 mg) plus dapagliflozin 10 mg or placebo plus dapagliflozin 10 mg. Changes in urinary albumin‐to‐creatinine ratio (UACR) and markers of fluid retention (bodyweight and B‐type natriuretic peptide [BNP]) were compared in participants with and without type 2 diabetes.

Results

Zibo/dapa 0.25/10 mg changed UACR by −37.7% (90% CI: −40.4, −23.4) compared to placebo/dapa in participants without diabetes and by −17.9% (90% CI: −31.3, −2.0) in participants with diabetes (p‐interaction 0.096). Effects of zibo/dapa 1.5/10 mg on UACR were consistent regardless of diabetes status (−34.0% (90% CI: −45.0, −20.8) vs. −33.0% (90% CI: −42.2, −22.5), p‐interaction 0.921). Changes in body weight and BNP did not differ by diabetes status. Fluid retention occurred in five participants with diabetes assigned to zibo/dapa 1.5/10 mg and one participant with diabetes in the zibo/dapa 0.25/10 mg group. Fluid retention did not occur in those without diabetes in both zibo/dapa groups. With placebo/dapa, fluid retention occurred in one participant without diabetes and in none with diabetes.

Conclusions

Combination therapy with zibotentan and dapagliflozin demonstrated consistent efficacy and safety across CKD patients with and without type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsDiabetes Mellitus, Type 2Renal Insufficiency, ChronicDiabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsEndothelin Receptor AntagonistsHumansMaleFemaleMiddle AgedDrug Therapy, CombinationDouble-Blind MethodAgedTreatment OutcomeAlbuminuriaHypoglycemic Agents

Stichwörter der Autor:innen

clinical trialdiabetes complicationsrandomised trialtype 2 diabetes

Substanzen

GlucosidesdapagliflozinBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsEndothelin Receptor AntagonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Centre for Kidney and Bladder Health, University College London, London, UK.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • George Institute for Global Health, Barangaroo, New South Wales, Australia.

ORCID-Profile: Victor Wasehuus, J David Smeijer, Phil Ambery, Peter Rossing, Hiddo J L Heerspink

Förderung

  • AstraZeneca

Zitieren

APA

Wasehuus, V., Smeijer, J. D., Ambery, P., Greasley, P. J., Wijkmark, E., Wheeler, D. C., Rossing, P., & Heerspink, H. J. L. (2025). Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16468

Vancouver

Wasehuus V, Smeijer JD, Ambery P, Greasley PJ, Wijkmark E, Wheeler DC, et al. Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16468

BibTeX
@article{Wasehuus2025,
  author = {Wasehuus, Victor and Smeijer, J David and Ambery, Phil and Greasley, Peter J and Wijkmark, Emma and Wheeler, David C and Rossing, Peter and Heerspink, Hiddo J L},
  title = {Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16468}
}
Kostenlos starten →